Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adicet Bio, Inc. (ACET : NSDQ)

• Company Description    Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $8.30 Daily Weekly Monthly 20 Day Moving Average: 100,558 shares Shares Outstanding: 9.35 (millions) Market Capitalization: $77.59 (millions) Beta: 1.50 52 Week High: $17.04 52 Week Low: $6.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.06% -0.07% 12 Week 13.39% 4.82% Year To Date -1.43% -13.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 131 DARTMOUTH STREET 3RD FLOOR - BOSTON,MA 02116 USA ph: 650-503-9095 fax: - abowdidge@adicetbio.com http://www.adicetbio.com

• General Corporate Information    Officers Chen Schor - President; Chief Executive Officer and Director Nick Harvey - Chief Financial Officer Jeffrey Chodakewitz - Director Steve Dubin - Director Michael Grissinger - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 007002207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 9.35 Most Recent Split Date: 12.00 (0.06:1) Beta: 1.50 Market Capitalization: $77.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-8.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 62.10% vs. Previous Quarter: 36.05% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -80.35 12/31/25 - -82.96 09/30/25 - -77.90 ROA 03/31/26 - -65.44 12/31/25 - -68.00 09/30/25 - -64.35 Current Ratio 03/31/26 - 7.66 12/31/25 - 7.47 09/30/25 - 5.62 Quick Ratio 03/31/26 - 7.65 12/31/25 - 7.47 09/30/25 - 5.62 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 14.98 12/31/25 - 16.62 09/30/25 - 20.98 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.01 12/31/25 - 0.00 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.61 12/31/25 - 0.40 09/30/25 - 0.57

Powered by Zacks Investment Research ©